Table 1 Possible clinical outcome-related pathways in lung adenocarcinoma.
From: Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma
Pathway | P value | Number ofsignificant genes (total gene number) | Significantly associated with survival in all four datasets | Significantly associated with survival in three datasets | Significantly associated with survival in two datasets |
|---|---|---|---|---|---|
Immune response_HMGB1/RAGE signalling pathway | 9.73E-08 | 21 (65) | V | ||
Development_Beta-adrenergic receptor regulation of ERK | 8.92E-06 | 22(70) | V | ||
Transport_Clathrin-coated vesicle cycle | 4.81E-06 | 31(107) | V | ||
Transport_RAN regulation pathway | 2.44E-06 | 16(47) | V | ||
Cell cycle_Role of Nek in cell cycle regulation | 1.34E-07 | 19(61) | V | ||
Development_Glucocorticoid receptor signalling | 8.63E-06 | 12(41) | V | ||
Immune response_IL-6 signalling pathway | 6.25E-07 | 13(33) | V | ||
Development_WNT signalling pathway. Part 2 | 2.56E-06 | 19(84) | V | ||
Cell cycle_Chromosome condensation in prometaphase | 7.34E-10 | 14(33) | V | ||
Cell cycle_Role of APC in cell cycle regulation | 1.23E-11 | 27(54) | V | ||
Development_WNT signalling pathway. Part 1. Degradation of beta-catenin in the absence of WNT signalling | |||||
4.67E-06 | 11(29) | V | |||
Cell cycle_Spindle assembly and chromosome separation | 3.06E-09 | 29(94) | V | ||
Cell cycle_Transition and termination of DNA replication | 1.27E-07 | 20(37) | V | ||
Cell cycle_Start of DNA replication in early S phase | 1.01E-06 | 16(43) | V | ||
Cell cycle_The metaphase checkpoint | 5.48E-06 | 14(36) | V |
